TransCode reports Q3 2023 operating loss of $5.3M; cash runway only into Jan 2024

Transcode Therapeutics, Inc.

2023-Q3 EPS reported -$8.46

Cash $7.5M at Sept 30, 2023, vs $5.0M at Dec 31, 2022; expects runway only into Jan 2024.
Operating loss $5.3M for Q3 2023 vs $4.3M in Q3 2022; R&D expense $3.3M, G&A $2.0M.
Dosed first patient in Phase 0 trial of TTX-MC138 in advanced solid tumors; no adverse reactions reported.
Closed public offering of 16.9M shares/pre-funded warrants at $0.51, gross proceeds ~$8.5M.
Plans to file IND for Phase I trial of TTX-MC138 and pursue orphan drug designations.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Transcode Therapeutics, Inc. reported financial results for third quarter ended September 30, 2023.

Period: third quarter ended September 30, 2023
Result: reported results

Exact text from the filing

TransCode Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2023

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Transcode Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-118180

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.